Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

E-ISSN： 1096-8652|90|11|967-969

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.11, 2015-11, pp. : 967-969

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 179-179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3612-3621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

By Gora-tybor Joanna Blonski Jerzy Z. Robak Tadeusz

Mediators of Inflammation, Vol. 12, Iss. 3, 2003-01 ,pp. : 167-171

Informa Healthcare

Access to resources Recommend Favorite

Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3788-3796

John Wiley & Sons Inc

Access to resources Recommend Favorite

“Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 375-382

John Wiley & Sons Inc

Access to resources Recommend Favorite